CORRECTION OF METABOLIC DISORDERS IN PARODONTAL TISSUES OF RATS CAUSED BY STREPTOZOCINININDUCED DIABETIC NEUROPATHY

Kotvytska A. A., Kryvoruchko T. D., Neporada K. S., Berehovyi S. M.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The prevalence of diabetes has increased significantly in recent years. The latest Diabetes Atlas IDF data shows that 0.5 billion adults worldwide live with diabetes. The most common complication of diabetes is peripheral diabetic neuropathy, which leads to the development of pathological changes in the nervous system and blood vessels and significantly reduces the quality of life of patients. An urgent problem today is the search for effective drugs to correct polyneuropathy and other complications of diabetes. Our attention was drawn to the metabolic drug Cocarnit, which contains 20 mg of nicotinamide, 50 mg of cocarboxylase, 500 mcg of cyanocobalamin, 10 mg of disodium adenosine triphosphate trihydrate. The aim of our study was to investigate the effectiveness of Cocarnit in the correction of periodontal syndrome in rats with diabetic polyneuropathy. Experimental diabetic polyneuropathy was simulated in experimental animals by a single injection of streptozocin (Streptozocin Sigma, USA). To confirm the development of diabetes on the 30th day of the experiment, a glucose tolerance test was performed. The development of diabetic neuropathy was assessed by measuring the pain sensitivity threshold using the Randall-Selitto strain-algometric test. The subjects of the study were periodontal tissues of rats in the homogenate which determined the content of TBA-active products, oxidatively modified proteins, free fucose, glycosaminoglycans, catalase activity, total proteolytic and antitryptic activity. Diabetic neuropathy has been shown to cause periodontal syndrome, as evidenced by a probable increase in total proteolytic activity with a significant increase in total antitryptic activity, increased free fucose and glycosaminoglycans, and intensification of free radical oxidation. The introduction of Cocarnit prevents the development of pathological changes in the periodontal tissues of rats in diabetic neuropathy.

diabetic neuropathy, periodontium, proteinase-inhibitory potential, oxidative stress, Cocarnit.

1. Tönnies T, Rathmann W, Hoyer A, Brinks R, Kuss O. Quantifying the underestimation of projected global diabetes prevalence by the International Diabetes Federation (IDF) Diabetes Atlas. BMJ Open Diabetes Research & Care 2021;9(1):e002122. DOI: https://doi. org/10.1136/bmjdrc-2021-002122.
2. Sempere-Bigorra M, Julián-Rochina I, Cauli O. Differences and similarities in neuropathy in type 1 and 2 diabetes: a systematic review. Journal of Personalized Medicine. 2021;11(3):230. DOI: https://doi.org/10.3390/jpm 11030230.
3. Yakobchuk SO, Iftodii AH, Kolotylo OB, Moskaliuk OP. Pytannia patohenezu diabetychnoi neiropatii. Bukovynskyi medychnyi visnyk. 2012;16(63):142-145. [in Ukrainian].
4. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nature Reviews Disease Primers. 2019;5(1):41. DOI: https://doi.org/10.1038/s41572-019-0092-1.
5. Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Therapeutic Advances in Chronic Disease. 2014;6(1):15-28. DOI: https://doi.org/10.1177/2040622314552071.
6. Beltramo E, Mazzeo A, Porta M. Thiamine and diabetes: back to the future? Acta Diabetologica. 2021;58:1433-1439. DOI: https://doi. org/10.1007/s 00592-021-01752-4.
7. Karaganis S, Song X. B vitamins as a treatment for diabetic pain and neuropathy. Journal of Clinical Pharmacy and Therapeutics. 2021;46:1199-1212. DOI: https://doi.org/10.1111/jcpt.13375.
8. Popov SV, Melekhovets’ OK, Demikhova NV, Vynnychenko LB. Drug with a high metabolic activity, cocarnit, in the treatment of diabetic cardiac autonomic neuropathy. Lik Sprava. 2012;3-4:75-81.
9. Kotov SV, Isakova EV, Leidvoll VY, Belova YA, Volchenkova TV, Borodin AV, et al. Effektivnost’ preparata kokarnit pri diabeticheskoy neyropatii. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;118(1):37-42. DOI: https://doi.org/10.17116/jnevro20181181137-42. [in Russian].
10. Nikitina N, Beregovyi S, Stepanova L, Kabanov O. Vyznachennya optymalʹnoyi skhemy vvedennya kokarnitu shchuram iz diabetychnoyu polineyropatiyeyu za dopomohoyu tenzoalhometrychnoho metodu. Visnyk Kyyivsʹkoho natsionalʹnoho universytetu imeni Tarasa Shevchenka. 2017;23(2):37-42. DOI: https://doi.org/10.17721/2616_6410.2017.23.37-42. [in Ukrainian].
11. Ugolev AM. Issledovanie pishchevaritel’nogo apparata u cheloveka. L.: Nauka; 1969. 216 s. [in Russian].
12. Veremeenko KN. Proteoliz v norme i pri patologii. K.: Zdorov’ya; 1988. 200 s. [in Russian].
13. Stal’naya ID, Garishvili TG. Metod opredeleniya malonovogo dial’degida s pomoshch’yu tiobarbiturovoj kisloty. Sovremennye metody v biokhimii. M.: Medicina; 1977. 392 s. [in Russian].
14. Dubinina EE. Okislitel’naya modifikaciya belkov syvorotki krovi cheloveka. Metod ee opredeleniya. Voprosy medicinskoj khimii. 1995;1:24- 26. [in Russian].
15. Korolyuk MA, Ivanova LI, Majorova IG. Metod opredeleniya aktivnosti katalazy. Laboratornoe delo. 1988;1:16-19. [in Russian].
16. Sharaev PN. Metod opredeleniya fukozy, nesvyazannoj s belkami. Klinicheskaya laboratornaya diagnostika. 1997;4:17-18. [in Russian].
17. Sharaev PN. Metod opredeleniya glikozaminoglikanov v biologicheskih zhidkostyah. Laboratornoe delo. 1987;5:530-532. [in Russian].

«Bulletin of problems biology and medicine» Issue 1 (163), 2022 year, 132-135 pages, index UDK 616.31-018-008.9-06:616.833-02:616.379-008.64-02:615.33]-08-092.9

10.29254/2077-4214-2022-1-163-132-135